Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07615166 · ClinicalTrials.gov registry record
Low-Density Lipoprotein Cholesterol Reduction With Alirocumab 150 mg Versus Inclisiran in Individuals Initiating Therapy in Routine Clinical Practice
A clinical trial, sponsored by Sanofi.
- Completed
- Registry status
- 996
- Enrollment target
NCT07615166 is a clinical trial that has completed, run by Sanofi. The registered enrollment target is 996 participants.
The verdict
NCT07615166 has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- 996 participants
- Enrollment target
Study Summary
The objective of this study is to evaluate LDL-C reduction over time among individuals initiating alirocumab 150 mg compared with inclisiran in routine clinical practice. The study will leverage observational data reflective of routine care and apply contemporary methods in target trial emulation and causal inference to estimate comparative treatment effects.
Interventions
- DRUG Inclisiran
- DRUG Alirocumab 150 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 996 participants |
| Start Date | 2025-05-22 |
| Est. Completion | 2026-06-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07615166
The ClinicalTrials.gov registry entry for NCT07615166 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 996 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Inclisiran is the first listed.
NCT07615166 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07615166 about?
NCT07615166 is a clinical study titled "Low-Density Lipoprotein Cholesterol Reduction With Alirocumab 150 mg Versus Inclisiran in Individuals Initiating Therapy in Routine Clinical Practice". The objective of this study is to evaluate LDL-C reduction over time among individuals initiating alirocumab 150 mg compared with inclisiran in routine clinical practice. The study will leverage observational data reflective of routine care and apply contemporary methods in target trial emulation an...
What is the current status of trial NCT07615166?
This trial is currently completed. The enrollment target is 996 participants. The study started on 2025-05-22. Estimated completion is 2026-06-30.
What interventions are being tested in trial NCT07615166?
The interventions under investigation include: Inclisiran (DRUG), Alirocumab 150 mg (DRUG).
Who is sponsoring clinical trial NCT07615166?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.